Oncotarget

Research Papers:

Study of single nucleotide polymorphisms of FBW7 and its substrate genes revealed a predictive factor for paclitaxel plus cisplatin chemotherapy in Chinese patients with advanced esophageal squamous cell carcinoma

Ying Liu _, Shu Ning Xu, Yong Shun Chen, Xiao Yuan Wu, Lei Qiao, Ke Li and Long Yuan

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:44330-44339. https://doi.org/10.18632/oncotarget.9736

Metrics: PDF 734 views  |   HTML 1141 views  |   ?  


Abstract

Ying Liu1,*, Shu Ning Xu1,*, Yong Shun Chen2, Xiao Yuan Wu1, Lei Qiao1, Ke Li1, Long Yuan3

1Department of Medical Oncology of Henan Cancer Hospital, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, Henan, China

2Department of Radiation Oncology of Henan Cancer Hospital, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, Henan, China

3Department of Surgical Oncology of Henan Cancer Hospital, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, Henan, China

*These authors have contributed equally to this work

Correspondence to:

Ying Liu, email: yaya7207@126.com

Keywords: paclitaxel, esophageal squamous cell carcinoma, chemotherapy, single nucleotide polymorphisms, FBW7

Received: December 09, 2015    Accepted: May 17, 2016    Published: May 31, 2016

ABSTRACT

Paclitaxel plays a major role in the treatment of advanced esophageal squamous cell carcinoma. However, there is no biomarker that could be used to predict the clinical response of paclitaxel. This work was conducted to investigate the association of genetic polymorphisms in FBW7 and its substrate genes and the clinical response of paclitaxel. Patients with advanced esophageal squamous cell carcinoma were treated with paclitaxel 175 mg/m2 over 3 hours day 1 and cisplatin 75 mg/m2 day 1, every 3 weeks. The genotypes of 11 FBW7 and its substrate gene polymorphisms were determined by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) method. Statistical analysis revealed that patients with mTOR rs1057079 AG (ORadjusted: 4.59; 95% CI: 1.78-11.86) genotype had significant correlation with the clinical response of paclitaxel when compared with AA genotype after adjustment for sex, age, and chemotherapy cycle. The median progression-free survival (PFS) of patients with advanced ESCC who received paclitaxel plus cisplatin (TP) as first-line treatment is 14.3 months (95% CI: 9.0-19.60 months). The median PFS (mPFS) of AG genotypes and AA genotypes in mTOR rs1057079 were 17.31 months (95% CI: 15.9-18.67 months) and 9.8 months (95% CI: 8.58-11.02 months) (p=0.019), respectively.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9736